HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
Christian Ammitzbøll Juul, Trine B. Engel, Frederikke P. Fliedner, Lars Ringgaard, Rasmus Eliasen, Fredrik Melander, Martin Bak, Andreas Kjær, Jonas R. Henriksen, Dennis Ringkjøbing Elema, Anders E. Hansen, Thomas L. Andresen
Topics & Concepts
LiposomeInternalizationOvarian cancerIn vivoChemistryCancer researchCancer cellOxaliplatinPEG ratioDrug deliveryAntibody opsonizationMononuclear phagocyte systemCancerPharmacologyReceptorIn vitroBiochemistryMedicineBiologyImmunologyInternal medicineOpsoninColorectal cancerFinanceEconomicsOrganic chemistryBiotechnologyMonoclonal and Polyclonal Antibodies ResearchCell Adhesion Molecules ResearchGlycosylation and Glycoproteins Research